C4 Therapeutics Inc (CCCC)
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies designed to degrade disease-causing proteins. Its lead candidate, Cemsidomide, is an orally available monodac intended to target IKZF1 and IKZF3 for use across multiple lines of therapy in multiple myeloma, and it has completed phase 1 testing. The company is also advancing CFT8919, an orally available allosteric bidac degrader directed at mutant epidermal growth factor receptor in non-small cell lung cancer, including the L858R mutation. In addition, C4 Therapeutics is working on degraders for inflammation, neuroinflammation, and neurodegeneration. The company has collaboration agreements with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., Merck KGaA, and Roche Holding AG for degrader-antibody conjugate development in cancer. Founded in 2015, it is headquartered in Watertown, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CCCC
|
$3.64
|
9.9% Upside
|
Fair
|
$13.33
|
302.8% Upside
|
Bargain
|
Fair
|
0.0%
|
October 29, 2026
|
1.6x
|
11.6x
|
407.2 M
|
162.4 M
|
12.3%
|
76.8%
|
-1.0
|
84.2%
|
